Active Share (vs S&P 500): 100.0%
· vs QQQ: 100.0%
— share of the book that differs from index weights (higher = more active)
· ranking
In its Q3 2026 13F filing, Bain Capital Life Sciences Investors, LLC disclosed 22 equity positions with a combined reported value of $1.45B. The filing implies a focused portfolio: its ten largest positions account for 84.0% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.
The largest disclosed positions as of Q3 2026 were KLRA ($257.90M), HTFL ($221.30M), VNDA ($134.18M). By sector, the heaviest allocations are Health Care 99.3%, Industrials 0.6%.
Versus the prior quarter, Bain Capital Life Sciences Investors, LLC opened 3 new positions, trimmed 3 and fully exited 2, a turnover rate of 33.3% of positions. The portfolio's overlap with the prior quarter was 79% of names.
The largest new positions opened in Q3 2026 were VNDA ($134.18M), TARS ($86.17M), DYN ($30.61M).
Of the 2 positions fully exited versus the prior quarter, the largest were DNTH ($35.33M), UPB ($4.16M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
Latest Bain Capital Life Sciences Investors, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
Bain Capital Life Sciences Investors, LLC files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 21 positions worth $1.68B in total. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).
Portfolio Structure
21 positions · $1.68B reported value (Q2 2026)
Top 10 holdings = 87.9% of reported value
Largest position: KLRA (KAILERA THERAPEUTICS INC) at 29.6%
Average position size: $80.10M
Sector Tilt
Health Care 99.0%
Industrials 0.9%
Materials 0.1%
(classified holdings cover 100% of value)
Quarterly Activity
Q2 2026: 2 new, 2 added, 7 reduced, 1 exited
10 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
AI Rebalance Analysis
1. Overall direction and market view: The fund reduced exposure to HTFL (-47.3% shares) and PHVS (-7.5% shares), added to ALKS (+62.6% shares), and initiated positions in VNDA and TARS, suggesting a selective approach to biotech/healthcare with a focus on pipeline potential and operational efficiency.
2. Key moves:
- Reduced: HTFL (47.3% shares), PHVS (7.5% shares).
- Added: ALKS (62.6% shares).
- New: VNDA, TARS.
3. Portfolio structure: Active, healthcare-focused (100% sector), moderate risk appetite (concentrated top-10 holdings at 83.9%), with tactical adjustments rather than broad overhauls.
4. Per-holding one-liner:
- KLRA: Kailera Therapeutics (biotech, unverified).
- HTFL: HeartFlow (medical imaging, unverified).
- VNDA: Vanda Pharmaceuticals (CNS drugs, unverified).
- ALKS: Alkermes (psychiatric/therapeutics, unverified).
- NAMS: NewAmsterdam Pharma (metabolic diseases, unverified).
- SVRA: Savara (pulmonary drugs, unverified).
- TARS: Tarsus Pharmaceuticals (eye/dermatology, unverified).
- PHVS: Pharvaris (orphan drugs, unverified).
- SLDB: Solid Biosciences (Duchenne muscular dystrophy, unverified).
- OLMA: Olema Pharmaceuticals (cancer, unverified).
5. Style summary: Biotech-focused fund with active rebalancing, trimming overvalued names and adding high-conviction pipeline plays.
Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice. · AI generated 2026-11-17 04:33
Predicts next-quarter Top-10 holdings and weights from the fund's own historical
trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative
volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through
quarter T. Weights are shares of the modelled portfolio.
The next-quarter predicted Top 10 (2026-Q4) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.
★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.
Barra Factor Attribution
The disclosed long US equity book from the 2026-Q3 13F is held at its
report-date weights and decomposed over 2026-09-30 ~ 2026-11-13.
The model uses 16 Barra style factors plus GICS sector dummies, WLS cross-sectional
factor returns and an EWMA factor covariance for risk. The “portfolio” is the
visible 13F book, not the fund's true NAV.
The quarter is not complete yet; the window ends at the latest available price date, 2026-11-13, and will update as prices arrive.
Portfolio return-17.19%Buy & hold
QQQ synthetic benchmark-13.72%Liquidity weighted
Excess return-3.47%vs benchmark
Barra annualised vol72.1%Model estimate
Realised vol61.7%Annualised in window
Weighted beta0.95Raw exposure
Factor / specific risk31% / 69%Share of variance
Top-10 concentration100.0%Of reported value
Start = 100. Red = portfolio, dark = QQQ synthetic benchmark, dashed grey = equal-weight model universe.
1. Performance
Metric
Value
Note
Portfolio return (buy & hold)
-17.19%
Disclosed long book
QQQ synthetic benchmark
-13.72%
Liquidity-weighted constituents
Model universe, equal weight
+0.30%
Opportunity-cost reference
Excess return
-3.47%
Portfolio − benchmark
Arithmetic return sum
-16.42%
Difference vs compounded is the cross term
Weighted raw beta
0.95
Weighted holding betas
Realised volatility (annualised)
61.67%
Daily returns in window
Barra model volatility (annualised)
72.07%
Factor + specific
Factor share of variance
30.8%
Barra factors
Specific share of variance
69.2%
Stock residuals
Reported value
$92.6M
13F long US equity
2. Return attribution
The -16.42% arithmetic return splits into style factors, sector factors and specific return; the table is sorted by contribution.
Factor group
Factors
Contribution
Share of |return|
Size & Liquidity
6
-0.05%
-0.3%
Momentum & Growth
3
-2.32%
-14.1%
Volatility & Tail Risk
7
+24.96%
152.0%
Industry
12
+8.12%
49.5%
Specific
1
-47.14%
-287.0%
Factor
Type
Exposure
Factor return
Contribution
Share of |return|
Kurtosis
Style
+3.30
+6.97%
+23.01%
140.1%
Skewness
Style
-3.06
-4.21%
+12.90%
78.5%
Health Care
Industry
+1.00
+8.12%
+8.12%
49.5%
Residual Volatility
Style
+2.03
+2.66%
+5.40%
32.9%
Size
Style
-1.66
-1.83%
+3.04%
18.5%
Non-linear Size
Style
+3.07
+0.91%
+2.81%
17.1%
Max Drawdown
Style
-1.28
-1.96%
+2.50%
15.2%
Beta
Style
+0.08
+4.85%
+0.41%
2.5%
Liquidity
Style
+1.45
+0.22%
+0.31%
1.9%
Momentum
Style
+0.02
-3.34%
-0.06%
-0.3%
Turnover
Style
+0.12
-4.77%
-0.58%
-3.5%
Amihud Illiquidity
Style
+2.75
-0.40%
-1.11%
-6.8%
Growth
Style
-1.46
+1.57%
-2.28%
-13.9%
Mid Cap
Style
+2.67
-1.69%
-4.52%
-27.5%
Leverage (Downside Vol)
Style
+3.59
-1.82%
-6.54%
-39.8%
Historical Volatility
Style
+0.99
-12.86%
-12.72%
-77.4%
Specific
Specific
—
—
-47.14%
-287.0%
3. Risk attribution
Annualised volatility is 72.07%; factor risk explains 30.8% of variance and specific risk 69.2%. A negative variance contribution means the factor is negatively correlated with the rest of the book and acts as a partial hedge.
Factor
Type
Exposure
Share of variance
Vol contribution
Share of vol
Specific
Specific
—
69.2%
+49.89%
49.9%
Leverage (Downside Vol)
Style
+3.59
5.7%
+4.14%
4.1%
Mid Cap
Style
+2.67
4.9%
+3.51%
3.5%
Health Care
Industry
+1.00
3.7%
+2.67%
2.7%
Growth
Style
-1.46
3.3%
+2.37%
2.4%
Non-linear Size
Style
+3.07
2.7%
+1.98%
2.0%
Residual Volatility
Style
+2.03
2.5%
+1.81%
1.8%
Historical Volatility
Style
+0.99
2.3%
+1.66%
1.7%
Size
Style
-1.66
2.0%
+1.43%
1.4%
Liquidity
Style
+1.45
1.8%
+1.29%
1.3%
Kurtosis
Style
+3.30
1.3%
+0.96%
1.0%
Amihud Illiquidity
Style
+2.75
1.3%
+0.92%
0.9%
Max Drawdown
Style
-1.28
1.2%
+0.88%
0.9%
Skewness
Style
-3.06
-1.9%
-1.38%
-1.4%
4. Style exposures
Standardised z-scores; positive means the book leans toward that style versus the model universe, negative means underweight.
Style factor
Portfolio
QQQ benchmark
Difference
Size
-1.66
+2.10
-3.76
Non-linear Size
+3.07
+1.68
+1.39
Mid Cap
+2.67
+0.13
+2.54
Beta
+0.08
+1.29
-1.21
Momentum
+0.02
+0.72
-0.70
Short-term Reversal
+0.02
-0.64
+0.66
Residual Volatility
+2.03
-0.40
+2.43
Historical Volatility
+0.99
+0.86
+0.13
Liquidity
+1.45
+0.11
+1.34
Amihud Illiquidity
+2.75
+1.16
+1.60
Turnover
+0.12
+0.21
-0.09
Growth
-1.46
+0.58
-2.04
Leverage (Downside Vol)
+3.58
+0.14
+3.44
Skewness
-3.06
+0.24
-3.30
Kurtosis
+3.30
+0.21
+3.08
Max Drawdown
-1.28
-0.08
-1.19
5. Industry allocation & Brinson
Sector
Portfolio
Benchmark
Portfolio ret
Benchmark ret
Allocation
Selection
Interaction
Total
Information Technology
0.0%
73.6%
+0.00%
-19.18%
+4.32%
+14.12%
-14.12%
+14.12%
Communication Services
0.0%
2.6%
+0.00%
-15.54%
+0.06%
+0.41%
-0.41%
+0.41%
Utilities
0.0%
0.8%
+0.00%
+11.58%
-0.20%
-0.09%
+0.09%
-0.09%
Consumer Staples
0.0%
0.8%
+0.00%
+15.58%
-0.24%
-0.13%
+0.13%
-0.13%
Consumer Discretionary
0.0%
8.8%
+0.00%
+5.56%
-1.66%
-0.49%
+0.49%
-0.49%
Industrials
0.0%
11.1%
+0.00%
+7.16%
-2.27%
-0.80%
+0.80%
-0.80%
Health Care
100.0%
1.7%
-17.19%
+9.16%
+22.08%
-0.46%
-25.89%
-17.35%
Total
+21.99%
+12.53%
-38.88%
-4.36%
6. Holdings & contribution
Symbol
Name
Sector
Weight
Return
Contribution
QoQ
NAMS
NEWAMSTERDAM PHARMA COMPANY
Health Care
100.00%
-17.19%
-17.19%
Hold
Contribution rank
Symbol
Sector
Weight
Return
Contribution
1
NAMS
Health Care
100.00%
-17.19%
-17.19%
7. Conclusions
Over the attribution window 2026-09-30 → 2026-11-13 (32 trading days), the reported portfolio returned -17.19%, versus -13.72% for the QQQ synthetic benchmark — an excess of -3.47%.
Return attribution: the largest positive style/industry contributions came from Kurtosis +23.01%, Skewness +12.90%, Health Care +8.12%; the largest drags came from Historical Volatility -12.72%, Leverage (Downside Vol) -6.54%, Mid Cap -4.52%. Specific (stock-level) return contributed -47.14%.
Risk attribution: Barra model volatility is 72.07% annualised; factor risk explains 31% of variance and specific risk 69%. The largest factor risk sources are Leverage (Downside Vol) 5.7%, Mid Cap 4.9%, Health Care 3.7%.
Style tilt: size -1.66, momentum +0.02, volatility +0.99, liquidity +1.45; the weighted raw beta is 0.95. Positive z-scores mean the portfolio leans toward that style versus the cross-section.
Industry: the largest overweight versus the benchmark is Health Care (+98.3 pp), the largest underweight is Information Technology (-73.6 pp). Allocation contributed +21.99%, selection +12.53% and interaction -38.88%.
Concentration: the top-10 positions are 100.0% of the attributed portfolio and the model covers 100.0% of its value with full style exposures. This is a high-conviction, long-only 13F book — not the fund's complete NAV.
Methodology & caveats
13F discloses long US equity (including some options) only; cash, shorts and non-US positions are absent. This is not the fund's true NAV.
Weights are the report-date reported values and stay fixed over the window (buy & hold); intra-quarter trading and flows are not captured.
Factor exposures are measured at quarter end and held through the next quarter; style factors are cross-sectionally orthogonalised and read as incremental exposures.
The database has no share-count data, so size and liquidity use dollar volume (price × volume) as a proxy; Size is closer to “traded-value scale”.
Factor returns come from a WLS cross-sectional regression on the model universe; risk is annualised, and some factor variance contributions can be negative.
13F filings lag by up to 45 days, so the stretch from the report date to the filing date was not actionable in real time.
Sector mapping uses one consistent GICS level-1 scheme for both the portfolio and the benchmark.
FAQ
What did Bain Capital Life Sciences Investors, LLC buy in 2026-Q3?
In its 2026-Q3 13F filing, Bain Capital Life Sciences Investors, LLC reported 22 equity positions worth $1.45B in aggregate; its largest disclosed positions were KLRA ($257.90M), HTFL ($221.30M), VNDA ($134.18M).
How large is Bain Capital Life Sciences Investors, LLC's portfolio?
Bain Capital Life Sciences Investors, LLC reported $1.45B of long equity holdings across 22 positions as of 2026-Q3. Top-10 holdings account for 84.0% of reported value.
What is Bain Capital Life Sciences Investors, LLC's investment style?
HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.
Embed this fund on your site
Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.
<iframe src="https://holdingshub.top/funds/bain-capital-life-sciences-investors/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>